恆偉集團(08219.HK)就收購口罩生產商權益訂諒解備忘錄
恆偉集團控股(08219.HK)公布,公司一間附屬公司與目標公司興創企業發展的股東訂立不具法律約束力的諒解備忘錄,公司擬向賣方收購目標公司的51%已發行股本。目標集團主要於香港從事生產及銷售一次性口罩。
目標集團在香港具備生產一次性口罩所必需的機器與原材料。一次性口罩已於3月開始生產。
集團指,已積極規劃運用無塵無污染潔淨室技術及設備,以生產醫用防護口罩,緩解本地短缺。倘建議交易落實,預計目標集團將設立無塵無污染潔淨室以生產醫用防護口罩,這將緩解本地短缺並滿足公眾對防疫產品的需求。除現有的手錶製造業務外,集團日後將考慮生產其他防疫產品,作為集團的長期策略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.